Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis

Summary

This is a randomized, double-blind, placebo-controlled, multicenter clinical trial in participants with moderate-to-severe plaque psoriasis .

Timeline

Start

2024-01-31

Primary completion

2024-11-01

Completion

2024-11-01

Outcome

Met primary endpoint

paper PASI 75 (85.0% to 90.0%, vs 12.5%, P < .001 for all) PMID 40967307 ↗

paper were achieved in patients receiving D-2570 at 18/27/36 mg versus placebo. PMID 40967307 ↗

release “在161名中、重度斑块状银屑病患者中，D-2570展示出显著优于安慰剂的疗效和良好的安全性，成功达到研究主要终点” inventisbio.com ↗

release “The primary endpoint of PASI 75 was achieved by a significantly greater proportion of patients in all D-2570 dose groups compared to placebo (p<0.001).” inventisbio.com ↗

Publications

• Zhang J, Zhou C, Miao G, Zhang S, Duan X, Wu L, Zhang G, Dang N, Ding Y, Han H, Wei A, Yang B, Li L, Li S, Dai X, Zhang J, Lei T, Yan W, Zhang L, Meng Z, Chen R, Song Q, Wang L, Wang W, Hu X, Xiang Z, Shi Z, Zhang L. Novel TYK2 inhibitor D-2570 in moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled, phase 2 trial. J Am Acad Dermatol. 2026 Jan;94(1):143-150. doi: 10.1016/j.jaad.2025.09.036. Epub 2025 Sep 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	D-2570	Unknown	18 mg	—
Subject	D-2570	Unknown	27 mg	—
Subject	D-2570	Unknown	36 mg	—

Indications